^
    1d
    Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (clinicaltrials.gov)
    P1, N=94, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    carboplatin • paclitaxel • veliparib (ABT-888)
    1d
    Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=155, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Nov 2026
    Trial completion date
    |
    BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    2d
    Surgical Pembro +/- Olaparib w TMZ for rGBM (clinicaltrials.gov)
    P2, N=78, Recruiting, L. Nicolas Gonzalez Castro, MD, PhD | Trial completion date: Nov 2026 --> Mar 2027 | Trial primary completion date: Feb 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • TERT (Telomerase Reverse Transcriptase)
    |
    EGFR mutation • EGFR amplification • IDH wild-type
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • temozolomide
    2d
    Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, University of Chicago | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    Tevimbra (tislelizumab-jsgr) • Partruvix (pamiparib) • hydroxyurea • fluorouracil topical
    2d
    Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    RAD51 (RAD51 Homolog A)
    |
    carboplatin • veliparib (ABT-888) • topotecan
    2d
    Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1/2, N=53, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    ERCC1 (Excision repair cross-complementation group 1) • XRCC1 (X-Ray Repair Cross Complementing 1)
    |
    carboplatin • paclitaxel • veliparib (ABT-888)
    2d
    COCOS: Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (clinicaltrials.gov)
    P2/3, N=582, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2026 --> Dec 2026
    Trial completion date • Platinum resistant
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    2d
    A Study of Serum Folate Levels in Patients Treated With Olaparib (clinicaltrials.gov)
    P4, N=10, Completed, Rush University Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    Lynparza (olaparib)
    3d
    Cancer metabolism in radiation sensitization: complementary roles of O-GlcNAc Transferase (OGT) and PARP1. (PubMed, J Cell Sci)
    The OGA inhibitor PUGNAc suppressed hyperresection due to PARP1 knockout while PARP inhibitor veliparib exacerbated defects in OGT- or EZH2-deficient cells. Our results highlight the potential of targeting cancer-associated metabolic reprogramming to overwhelm HR repair and drive resection stress. Combining PARP inhibition with blockade of O-GlcNAcylation or EZH2 may offer a strategy to radiosensitize proliferating, HR-proficient cancers while sparing non-cycling normal tissues.
    Journal
    |
    BRCA1 (Breast cancer 1, early onset) • RAD51 (RAD51 Homolog A) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • OGA (O-GlcNAcase)
    |
    veliparib (ABT-888)
    3d
    Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2026 --> Nov 2026
    Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • Recentin (cediranib)
    3d
    NRG-GY004: Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)
    P3, N=579, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Aug 2026 --> Nov 2026
    Trial completion date • Platinum sensitive
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    3d
    A021804: Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer (clinicaltrials.gov)
    P2, N=46, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Mar 2028 | Trial primary completion date: Feb 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    Lynparza (olaparib) • temozolomide